HOME >> BIOLOGY >> NEWS
Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic

Scientists report that an unlikely molecule has emerged as an attractive target for development of therapeutics aimed at a diverse spectrum of tumors, including some malignancies that are resistant to conventional therapies. Two studies published online in Cancer Cell demonstrate that the insulin-like growth factor 1 receptor (IGF-1R) is required for the survival of tumor cells and provide direct evidence that inhibition of IGF-R1 using selective small molecules represents a novel potential anticancer treatment.

Extensive studies have suggested that IGF-1R plays a role in the development of human cancers. IGF-1R is present in a broad range of tumor types including multiple myeloma, lymphoma, leukemia, and breast, lung, prostate, and colon cancers. However, IGF-1R has not been viewed as a likely target for cancer therapeutics because many normal cells also contain the protein. Research scientists from Dana-Farber Cancer Institute in Boston and Novartis Institutes for Biomedical Research Basel demonstrate that IGF-1R inhibition using a variety of methods had potent antitumor effects against many types of cancer cells grown in the laboratory, including cells that are resistant to conventional cancer therapeutics.

Molecular analyses demonstrated that IGF-1R inhibition impacts multiple intracellular signals related to cell proliferation or tumor development and provides possible mechanisms to explain how IGF-1R inhibition can make tumor cells more sensitive to conventional chemotherapy or other anticancer agents. Perhaps most significantly, IGF-1R suppresses tumor growth, prolongs survival, and enhances the antitumor effect of chemotherapy in clinically relevant mouse models of multiple myeloma and other hematological malignancies. The researchers also identify two small molecules that are selective inhibitors of IGF-1R and are active anticancer agents against tumors that contain IGF-1R. These small molecules represent highly attractive potential therapeu
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
26-Feb-2004


Page: 1 2

Related biology news :

1. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
2. Inhibition of Borrelia burgdorferi protein may reduce Lyme disease transmission
3. Inhibition Of A Novel Gene Involved In Phosphorylating Starch In TransgenicPotato Tubers Leads To The Repression Of Cold Induced Sweetening
4. Competitive Inhibition May Enhance Safety Of Minimally Processed Fruits And Vegetables
5. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
6. New Arizona State center brings science to policy on issues of water resources and urban growth
7. Researchers identify protein promoting vascular tumor growth
8. IBD (Crohns, Colitis) joins cancer, inflammatory diseases in associated blood vessel growth
9. Growth hormone and IBD: Reduction of intestinal inflammation, promotion of growth
10. Extreme stretch-growth of axons
11. Diabodies act as guided missiles targeted to mammary tumor growth

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2019)... ... January 31, 2019 , ... ... NC, providing full, customizable clinical research services across multiple therapeutic areas, announced ... for early stage life science entrepreneurs in the Research Triangle region of ...
(Date:1/25/2019)... ... January 24, 2019 , ... GrowthZone, Inc., ... Survey. The report indicates membership growth in some sectors and decreasing membership among ... received responses from over 500 association professionals across North America. , “This ...
(Date:1/20/2019)... , ... January 16, 2019 , ... As the leader ... through the introduction of its own liver 3D cell culture models. In an effort ... models, protocols and validation criteria so that any researcher can replicate these models for ...
Breaking Biology News(10 mins):
(Date:2/6/2019)... ... February 05, 2019 , ... Firmex announced today that ... to acquire Firmex, one of the fastest-growing and most widely-used providers of virtual ... firm. Debt financing was provided by the Bank of Montreal. , Headquartered in ...
(Date:2/2/2019)... ... January 31, 2019 , ... Dust off your Doc Martens, Virun ... the Nuriv 2019 Expo West Music and Tech Festival at the ESports Arena in ... in the natural foods, beverages, and dietary supplement industries, the Nuriv Music and Tech ...
(Date:2/2/2019)... ... February 01, 2019 , ... Biomatlante, a world ... its new CEO, Julien Dert, being effective on February 1st, 2019. , Graduated ... and management, in which more than 12 years in the Medical Device industry. ...
(Date:1/30/2019)... ... January 29, 2019 , ... ... Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in ... million backed by multiple global investors lead by China's State Development & Investment ...
Breaking Biology Technology:
Cached News: